LeMaitre Vascular

LeMaitre Vascular, Inc. engages in the provision of medical devices and human tissue cryopreservation services. The company focuses on the design, marketing, sales, service, and technical support of medical devices and implants for the treatment of peripheral vascular disease. Its products include balloon catheters, carotid shunts, biologic patches, radiopaque marking tape, anastomotic clips, remote endarterectomy devices, laparoscopic cholecystectomy devices, vascular grafts, and powered phlebectomy. The company was founded by George D. LeMaitre on November 28, 1983 and is headquartered in Burlington, MA.

Earnings data Q1 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

LeMaitre Vascular, Inc. (NASDAQ:LMAT ) Q1 2023 Earnings Conference Call May 2, 2023 5:00 PM ET Company Participants Joseph Pellegrino - Chief Financial Officer George LeMaitre - Chairman and Chief Executive Officer David Roberts - President Conference Call Participants Brett Fishbin - KeyBanc Capital Markets Inc. Frederick Wise - Stifel, Nicolaus & Company, Inc. Michael Petusky - Barrington Research Associates, Inc. Scott Henry - ROTH Capital Partners Operator Welcome to the LeMaitre Vascular Q1 2023 Financial Results Conference Call. As a reminder, today's call is being recorded.

LeMaitre Vascular, Inc. (LMAT) Q1 2023 Earnings Call Transcript

LeMaitre Vascular (LMAT) came out with quarterly earnings of $0.27 per share, beating the Zacks Consensus Estimate of $0.25 per share. This compares to earnings of $0.27 per share a year ago.

LeMaitre Vascular (LMAT) Q1 Earnings and Revenues Beat Estimates

BURLINGTON, Mass., May 02, 2023 (GLOBE NEWSWIRE) -- LeMaitre (Nasdaq:LMAT), a provider of vascular devices, implants and services, today reported Q1 2023 results, announced a $0.14/share quarterly dividend and provided guidance.

LeMaitre Q1 2023 Financial Results

Zimmer Biomet Hlds

Investors with an interest in Medical - Products stocks have likely encountered both Zimmer Biomet (ZBH) and LeMaitre Vascular (LMAT). But which of these two stocks offers value investors a better bang for their buck right now?

ZBH or LMAT: Which Is the Better Value Stock Right Now?

BURLINGTON, Mass., April 20, 2023 (GLOBE NEWSWIRE) -- LeMaitre Vascular, Inc. (Nasdaq: LMAT), a provider of vascular devices, implants and services, announced today it has entered into an agreement with Aziyo Biologics, Inc. (Nasdaq: AZYO) to become the exclusive distributor of Aziyo's cardiovascular patches in the United States. Under the agreement, LeMaitre will distribute the products for three years and has an option to acquire Aziyo's worldwide cardiovascular patch business during the second and third year of the term.

LeMaitre to Distribute Aziyo Biologics' Cardiovascular Patches

BURLINGTON, Mass., April 17, 2023 (GLOBE NEWSWIRE) -- LeMaitre Vascular, Inc. (Nasdaq:LMAT) announced today that it will release its first quarter 2023 financial results on Tuesday, May 2, 2023, after the market close. The company has scheduled a conference call for 5:00 PM ET the same day to discuss the results, business highlights, and company outlook.

LeMaitre Will Announce First Quarter 2023 Earnings Results May 2, 2023

Amgen

Amgen and LeMaitre Vascular both possess solid product portfolios and pipelines to drive future earnings growth. Their payouts are well-covered by their earnings.

Income Investors: These 2 Stocks Have Quadrupled Their Dividend Payouts Over the Past 10 Years

ZBH vs. LMAT: Which Stock Is the Better Value Option?

BURLINGTON, Mass., March 14, 2023 (GLOBE NEWSWIRE) -- LeMaitre Vascular, Inc. (Nasdaq: LMAT), a provider of vascular devices, implants and services, today announced that it has signed a definitive agreement to buy out its Thai distributor, Prompt Serve, for $688,000. In 2022 Prompt Serve purchased $950,000 of LeMaitre devices which it then sold to Thai hospitals for approximately $1.5mm. LeMaitre expects to establish a Bangkok office/warehouse and to begin selling directly to Thai hospitals in H2 2023. This will be LeMaitre's 29th direct-to-hospital country and follows LeMaitre's Korean distributor buyout in 2022. Korea and Thailand were previously LeMaitre's two largest international distributors.

LeMaitre to Go Direct in Thailand

LeMaitre Vascular's results were mixed in the fourth quarter. The company could maintain high dividend growth moving forward.

Buy This Under-the-Radar Stock for Dividend Growth

BURLINGTON, Mass., March 03, 2023 (GLOBE NEWSWIRE) -- LeMaitre Vascular, Inc. (Nasdaq:LMAT) announced today that management will be participating in four upcoming investor conferences in March.

LeMaitre to Participate at Upcoming Investor Conferences in March

Reasonable growth vertically throughout P&L and cash flows, exhibiting strength in major markets. Growth in rep headcount converting at the top line looks to further growth in reps in FY23.

LeMaitre: Remaining Constructive On Long-Term Valuations

Assured Guaranty

BlackRock

BWX Technologies

Commerce Bancshares

Cogent Communications Holdings

Canadian National Railway Company

eBay

Elevance Health Inc

Equinix

Evans Bancorp

Exponent

Comfort Systems USA

Genpact

Gaming and Leisure Properties

Home Depot

Jack Henry & Associates

Kforce

Kimberly-Clark

L3Harris

Louisiana-Pacific

Northrim BanCorp

Public Service Enterprise Group

Perrigo

All stocks have at least five fiscal years of dividend growth history and come from the U.S. Dividend Champions List. They have an average increase of 8.3% and a median increase of 8.1%.

32 Upcoming Dividend Increases Including 2 Dividend Kings

LeMaitre Vascular, Inc. (NASDAQ:LMAT ) Q4 2022 Earnings Conference Call February 23, 2023 5:00 PM ET Company Participants J.J. Pellegrino - Chief Financial Officer George LeMaitre - Chairman and Chief Executive Officer Dave Roberts - President Conference Call Participants Matthew Mishan - KeyBanc Michael Petusky - Barrington Research Brooks O'Neil - Lake Street Capital Jim Sidoti - Sidoti Operator Welcome to LeMaitre Vascular Q4 2022 Financial Results Conference Call.

LeMaitre Vascular, Inc. (LMAT) Q4 2022 Earnings Call Transcript

LeMaitre (LMAT) delivered earnings and revenue surprises of -3.85% and 0.57%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?

LeMaitre Vascular (LMAT) Q4 Earnings and Revenues Lag Estimates

BURLINGTON, Mass., Feb. 23, 2023 (GLOBE NEWSWIRE) -- LeMaitre (Nasdaq:LMAT), a provider of vascular devices, implants and services, today reported Q4 2022 results, announced a $0.14/share quarterly dividend (+12%) and provided guidance.

LeMaitre Q4 2022 Financial Results

BURLINGTON, Mass., Feb. 08, 2023 (GLOBE NEWSWIRE) -- LeMaitre Vascular, Inc. (Nasdaq:LMAT) announced today that it will release its fourth quarter 2022 financial results on Thursday, February 23, 2023, after the market close. The company has scheduled a conference call for 5:00 PM ET the same day to discuss the results, business highlights, and company outlook.

LeMaitre Will Announce Fourth Quarter 2022 Earnings Results February 23, 2023

Varex Imaging

VREX vs. LMAT: Which Stock Is the Better Value Option?

LeMaitre Vascular isn't well-known to investors. But vascular surgeons do know the company well.

Is This Small-Cap Dividend Stock a Buy?

EssilorLuxottica SA

ESLOY vs. LMAT: Which Stock Is the Better Value Option?

ESLOY vs. LMAT: Which Stock Should Value Investors Buy Now?

ESLOY or LMAT: Which Is the Better Value Stock Right Now?

Missed top line estimates secondary to FX headwinds and market challenges. Balance sheet remains healthy with adequate cash to deploy for acquisitions, sales rep investments.

LeMaitre: Balance Sheet Ready To Unlock Risk Capital, Reaffirm Buy

The medical device maker flies under the radar of most investors.

Is This Underfollowed Dividend Stock a Buy?

BURLINGTON, Mass., Nov. 22, 2022 (GLOBE NEWSWIRE) -- LeMaitre Vascular, Inc. (Nasdaq:LMAT) announced today that it is participating in two upcoming investor conferences.

LeMaitre to Present at Upcoming Investor Conferences

News for LeMaitre Vascular Stock (LMAT)